FGFR2 and breast carcinoma: In human breast cancer, FGFR2 moves to the nucleus after activation by extracellular ligands; however, the commercial ATP pocket inhibitor PD173074 blocks this agonist-induced FGFR2 nuclear translocation and inhibits RTK activity and downstream pathways [30,36].